



# Publisher Correction to: Adenosine receptor signalling in Alzheimer's disease

Phuc N. H. Trinh<sup>1,2</sup> · Jo-Anne Baltos<sup>1,2</sup> · Shane D. Hellyer<sup>1</sup> · Lauren T. May<sup>1,2</sup> · Karen J. Gregory<sup>1,3,2</sup>

Published online: 16 November 2022  
© Springer Nature B.V. 2022

## Abstract

Alzheimer's disease (AD) is the most common dementia in the elderly and its increasing prevalence presents treatment challenges. Despite a better understanding of the disease, the current mainstay of treatment cannot modify pathogenesis or effectively address the associated cognitive and memory deficits. Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets for Alzheimer's disease. The adenosine A1 and A2A receptors are expressed in the human brain and have a proposed involvement in the pathogenesis of dementia. Targeting these receptors preclinically can mitigate pathogenic  $\beta$ -amyloid and tau neurotoxicity whilst improving cognition and memory. In this review, we provide an accessible

summary of the literature on Alzheimer's disease and the therapeutic potential of A1 and A2A receptors. Although there are no available medicines targeting these receptors approved for treating dementia, we provide insights into some novel strategies, including allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic response.

This article is part of the Special Issue "Purinergic Signalling – Perspectives from Australia and New Zealand", Guest Editors: Ronald Sluyter, School of Chemistry and Molecular Bioscience, University of Wollongong, Australia; Jennie Cederholm, School of Medical Sciences (SoMS), UNSW Sydney, Australia; Srdjan Vlajkovic, Dept. of Physiology, University of Auckland, New Zealand;

It was unintentionally published in issue 18, 359–381 (2022). You can access the article via this link: <https://link.springer.com/article/10.1007/s11302-022-09883-1>. We apologise for the inconvenience.

The original article can be found online at <https://doi.org/10.1007/s11302-022-09883-1>.

✉ Lauren T. May  
lauren.may@monash.edu

✉ Karen J. Gregory  
karen.gregory@monash.edu

Phuc N. H. Trinh  
phuc.trinh@monash.edu

Jo-Anne Baltos  
joanne.baltos@monash.edu

Shane D. Hellyer  
shane.hellyer@monash.edu

- <sup>1</sup> Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
- <sup>2</sup> Department of Pharmacology, Monash University, Parkville, VIC 3052, Australia
- <sup>3</sup> ARC Centre for Cryo-Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Parkville 3052, Australia

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.